| Code: MTA14596 | Publication Date: Oct 2026 |
The following is a data-backed list of the leading T Cell Lymphoma companies, compiled through 6Wresearch's proprietary research and validated by in-house industry analysts. 4SC AG, Bristol Myers Squibb currently lead the competitive landscape, alongside several other established players shaping the Global T Cell Lymphoma Market.
For detailed forecasts, data tables, and competitive benchmarking,
Explore the full Global T Cell Lymphoma Market.
| Company Name | 4SC AG |
|---|---|
| Established Year | 1997 |
| Headquarters | Planegg-Martinsried, Germany |
| Official Website | Click Here |
Description: 4SC AG is a biopharmaceutical company focused on discovering and developing small-molecule targeted cancer therapies based on epigenetic mechanisms of action, including resminostat for peripheral T-cell lymphomas.
| Company Name | Bristol Myers Squibb |
|---|---|
| Established Year | 1887 |
| Headquarters | New York City, New York, United States |
| Official Website | Click Here |
Description: Bristol Myers Squibb is a global biopharmaceutical leader specializing in innovative oncology, hematology, and immun-oncology therapeutics, including targeted therapies evaluated for various blood cancers and T-cell lymphomas.
| Company Name | Atara Biotherapeutics |
|---|---|
| Established Year | 2012 |
| Headquarters | Thousand Oaks, California, United States |
| Official Website | Click Here |
Description: Atara Biotherapeutics is a pioneer in allogeneic T-cell immunotherapy, utilizing its off-the-shelf Epstein-Barr virus (EBV) T-cell platform to develop novel cellular therapies for hematologic malignancies and hard-to-treat lymphomas.
| Company Name | Takeda Pharmaceutical Company Limited |
|---|---|
| Established Year | 1781 |
| Headquarters | Tokyo, Japan |
| Official Website | Click Here |
Description: Takeda Pharmaceutical is a R&D-driven global biopharmaceutical leader focused on oncology and rare diseases, known for delivering targeted therapies such as brentuximab vedotin.
| Company Name | Acrotech Biopharma |
|---|---|
| Established Year | 2018 |
| Headquarters | East Windsor, New Jersey, United States |
| Official Website | Click Here |
Description: Acrotech Biopharma is a commercial-stage biopharmaceutical company focused on commercializing innovative cancer therapies, including belinostat for relapsed or refractory peripheral T-cell lymphoma.
| Company Name | CRISPR Therapeutics |
|---|---|
| Established Year | 2013 |
| Headquarters | Zug, Switzerland |
| Official Website | Click Here |
Description: CRISPR Therapeutics is a gene editing company developing transformative gene-based medicines using its proprietary CRISPR/Cas9 platform.
| Company Name | March Biosciences |
|---|---|
| Established Year | 2022 |
| Headquarters | Houston, Texas, United States |
| Official Website | Click Here |
Description: March Biosciences is a clinical-stage cell therapy company developing targeted CAR-T cell therapeutics, including its lead candidate MB-105 targeting CD5 to treat relapsed or refractory T-cell lymphoma and leukemia.
| Company Name | Seagen Inc. |
|---|---|
| Established Year | 1997 |
| Headquarters | Bothell, Washington, United States |
| Official Website | Click Here |
Description: Seagen, now part of Pfizer, is a pioneer in antibody-drug conjugate (ADC) technologies, best known for developing groundbreaking therapies like ADCETRIS targeting CD30-expressing peripheral T-cell lymphomas.
| Company Name | Shenzhen Chipscreen Biosciences Co., Ltd. |
|---|---|
| Established Year | 2001 |
| Headquarters | Shenzhen, Guangdong, China |
| Official Website | Click Here |
Description: Shenzhen Chipscreen Biosciences is a biotech enterprise in China specializing in chemical genomics and original drug discovery and developer of Chidamide (epidaza).
ISO 9001:2015 CERTIFIED
Quality Management System for market research & advisory services
Cert. No. 3050261008135Q